Sorry, you need to enable JavaScript to visit this website.

Skip to main content
This section of the global Janssen website provides a company overview in several languages. It is not targeted to any specific audience or country. Click here for country- and region-specific information of interest.
 
 
 
 
MENU

JANSSEN GLOBAL
change location >

Search
Search

Press Releases

Latest News Releases

Go

Jan 07, 2019

Belgium

Janssen Submits Application to European Medicines Agency Seeking Approval of STELARA® (ustekinumab) for Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis

Dec 20, 2018

United States

Janssen Submits Application To U.S. FDA Seeking Approval Of STELARA® (ustekinumab) For Treatment Of Moderately To Severely Active Ulcerative Colitis

Dec 20, 2018

Belgium

Janssen Announces European Commission Approval of Darzalex®▼ (daratumumab) Split Dosing Regimen

Dec 13, 2018

United States

Janssen Signs Results-Based Contract with Oklahoma Health Care Authority (OHCA) for its Long-Acting Injectable Schizophrenia Medicines

Dec 12, 2018

United States

New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48

Dec 05, 2018

New Phase 3 CASSINI Data Presented on the Use of XARELTO® (rivaroxaban) for Venous Thromboembolism (VTE) Prevention in High-Risk Cancer Patients

Dec 04, 2018

New Phase 3 Study Findings Show IMBRUVICA® (ibrutinib) Plus Rituximab Significantly Improved Survival Compared to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Previously Untreated Patients Aged 70 or Younger with Chronic Lymphocytic Leukemia

Dec 04, 2018

New DARZALEX® (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of Anti-CD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma

Dec 03, 2018

United States

Updated Data from Phase 1/2 Open-Label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Tolerable Safety Profile, High Overall Response and MRD Negative Rate in Treatment of Patients with Advanced Relapsed or Refractory Multiple Myeloma

Dec 03, 2018

United States

IMBRUVICA® (ibrutinib) Plus Obinutuzumab Showed Significant Improvement in Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Go